Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
April 05, 2021
Podcast
In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.
March 30, 2021
Article
Narjust Duma, MD, has been named as the new associate director of the Cancer Care Equity Program at the Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School.
March 29, 2021
Video
Nikhil C. Munshi, MD, discusses the FDA approval of idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
March 20, 2021
Article
Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.
March 11, 2021
Video
Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.
March 09, 2021
Article
Corey S. Cutler, MD, MPH, FRCPC, discusses the potential clinical implications should belumosudil gain FDA approval in chronic GVHD.